The Joint Clinical Assessment and rare disease
One EU-wide review of clinical value. Twenty-seven national decisions still to win. For rare and orphan products, the JCA is the hardest test yet — and 2028 is closer than it looks.
Author
Systemix Health
Published
6 July 2026
One EU-wide review of clinical value. Twenty-seven national decisions still to win. For rare and orphan products, the JCA is the hardest test yet, and 2028 is closer than it looks.
01What it is
The Joint Clinical Assessment (JCA) is a single, EU-wide review of a medicine's clinical value. It runs under the HTA Regulation (EU) 2021/2282. It went live on 12 January 2025.
One assessment now replaces the duplicated clinical reviews that each member state ran on its own. A joint team of assessors examines the relative effects of a new health technology on health outcomes. The result is a scientific report. Member states draw on that report in their national health technology assessment.
The JCA does not set a price. It does not decide reimbursement. It reaches no conclusion on value for money. Those choices stay national. The JCA answers the clinical question only, and it answers it once for the whole Union.
Oncology and advanced therapy medicinal products are in scope today. Many of these are already orphan products. Orphan medicinal products as a class join in 2028. That is the deadline every rare disease developer should now be planning around.
02Why it matters for rare disease
Rare disease is where the JCA bites hardest. The evidence that orphan products can realistically generate is the evidence the method is most cautious about.
Most national systems have learned to work with the constraints of rare disease. Small populations. Single-arm trials. Natural history studies. Real-world evidence as the only comparator available. The current JCA methods guidance is far less accommodating. It is cautious on real-world evidence and external control arms, which for many orphan products are the only evidence there is. Assessed once for the whole Union, that gap is exposed everywhere at once.
The scope compounds the problem. A JCA can carry many PICOs: population, intervention, comparator, outcomes. Each member state can request its own comparators and subpopulations. In a common disease that is demanding. In a rare disease with an unclear or shifting standard of care, it can produce a large set of indirect treatment comparisons against comparators that barely exist. The submission window is tight. As currently set, the dossier is due within 90 days of the request, in parallel with EMA review.
The Coordination Group defines the PICOs and comparators after the EMA filing.
The developer submits clinical evidence against the full scope, on a fixed deadline.
Assessors publish a joint report. Member states then run national pricing and reimbursement.
03Who it is for
- Orphan drug developers, above all.Single-arm trials, natural history studies and real-world evidence sit awkwardly against current JCA methods guidance. Comparators are often unclear. The exposure is real and the 2028 clock is already running.
- Oncology and advanced therapy teams already in scope.Many of these products carry orphan designation. They are the live proving ground for how the JCA will treat rare indications from 2028.
- Market access, HEOR, medical affairs, regulatory and clinical development leaders.In a small-population setting, evidence strategy, comparator selection and PICO planning now cut across all of these functions at once.
- Investors and diligence teams backing rare disease assets.A weak JCA position is a commercial risk that belongs in the model. For an orphan asset with thin comparator evidence, it is worth pricing before the term sheet.
04Key insights
The clinical case is now an EU case.
Plan the evidence for every market from the first-in-human study. In a rare disease you rarely get a second cohort to fix it later.
Comparators are the orphan drug trap.
Standard of care is often unclear or shifting. Map every plausible comparator each member state might name, then simulate the PICO set early and often.
Defend your real-world and single-arm evidence.
For many orphan products it is the only evidence there is. Build the case for external control arms and natural history data before guidance forces the question.
The 90-day clock is unforgiving.
The dossier runs against a fixed deadline in parallel with EMA. With a large PICO set and thin comparators, late preparation gets expensive fast.
Joint Scientific Consultation is the cheapest lever.
Use a JSC to align on evidence expectations before the trial locks. For a rare indication it is the single best way to reduce JCA risk.
National decisions still decide access.
The JCA informs. It does not reimburse. Local value stories, clinical opinion leaders and payer engagement still determine which patients get the treatment.
2028 is not far away.
For an early 2028 orphan filing, the groundwork should already have started in late 2025. If it has not, start now.
Systemix Health is a rare disease intelligence consultancy. We help orphan drug developers turn a strong molecule into a defensible EU access position, long before the 90-day clock starts.
- Rare disease landscaping. The patient pathway, the true standard of care, and every comparator a member state might name.
- PICO and comparator readiness. Simulate the likely PICO set, expose the gaps, and plan the indirect comparisons early.
- Evidence and TPP validation. Stress-test single-arm, natural history and real-world evidence against JCA expectations.
- Barrier and driver analysis. Map the national payers and clinical opinion leaders who shape each verdict, kept current through automated field monitoring.
- Diligence support. Price the JCA risk in a rare disease asset before the term sheet.